Tibet Pharmaceuticals (600211.SH) released its performance for the first three quarters, with net profit attributable to shareholders of RMB 776 million, up 7.48% year on year.

Zhitong Finance APP News, Tibet Pharmaceuticals (600211.SH) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 2.176 billion yuan, a year-on-year increase of 4.15%; net profit attributable to shareholders of the listed company was 776 million yuan, a year-on-year increase of 7.48%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 609 million yuan, a year-on-year decrease of 8.91%; basic earnings per share were 2.41 yuan.